<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407537</url>
  </required_header>
  <id_info>
    <org_study_id>A3841047</org_study_id>
    <nct_id>NCT00407537</nct_id>
  </id_info>
  <brief_title>Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors</brief_title>
  <acronym>CRUCIAL</acronym>
  <official_title>A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether a Caduet based treatment strategy might result in greater reduction in
      total cardiovascular risk as compared to usual care in subjects with hypertension and
      additional risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Framingham 10-year Risk of Total CHD at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European SCORE 10-year Risk of Fatal CVD at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham 10-year Risk of Stroke at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific &quot;calibration factor&quot; for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham 10-year Risk of Stroke at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific &quot;calibration factor&quot; for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Framingham 10-year Risk of Developing Total CHD</measure>
    <time_frame>Baseline, Month 4, Month 12</time_frame>
    <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD</measure>
    <time_frame>Baseline, Month 4, Month 12</time_frame>
    <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic and Diastolic Blood Pressure at Month 4</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic and Diastolic Blood Pressure at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DBP at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Lipid Parameters at Month 4</measure>
    <time_frame>Month 4</time_frame>
    <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Lipid Parameters at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Parameters at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Parameters at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months</measure>
    <time_frame>Month 4, Month 12</time_frame>
    <description>Goals set at &lt;140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and &lt;140/90 mm Hg or &lt;130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months</measure>
    <time_frame>Month 4, Month 12</time_frame>
    <description>Goal set at &lt;100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at &lt;80 mg/dL according to the European (EU) Society of Cardiology guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months</measure>
    <time_frame>Month 4, Month 12</time_frame>
    <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase of Treatment Dosages After 4 Months.</measure>
    <time_frame>Month 4</time_frame>
    <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1531</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Caduet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label caduet added to usual care regimen followed by investigators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate/atorvastatin calcium single pill combination</intervention_name>
    <description>Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion</description>
    <arm_group_label>Caduet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension with three additional risks factors (for example: smoking, type 2
             diabetes, family history of early heart disease, history of stroke, age over 55 (men)
             and 65 (women)

        Exclusion Criteria:

          -  Subjects currently receiving a statin or stopped statin within 6 months prior to
             enrollment.

          -  Subjects with a history of myocardial infarction and subjects with coronary bypass
             graft or intra-coronary interventions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Desamparados</city>
        <state>San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heredia</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Breznicki Hum</city>
        <zip>42225</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cakovec</city>
        <zip>40000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Crikvenica</city>
        <zip>51260</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Karlovac</city>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spisic Bukovica</city>
        <zip>33404</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sv. Kriz Zacretje</city>
        <zip>49223</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Varazdin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Klatovy</city>
        <zip>339 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kralupy nad Vltavou</city>
        <zip>278 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lanskroun</city>
        <zip>563 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pelhrimov</city>
        <zip>393 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>186 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pruhonice</city>
        <zip>252 43</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>400 07</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vratimov</city>
        <zip>739 32</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zlin 4</city>
        <zip>763 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Cristobal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santo Domingo</city>
        <zip>4966</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cilandak</city>
        <state>Jakarta Selatan</state>
        <zip>12430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bandung</city>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Semarang</city>
        <zip>50231</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Surabaya</city>
        <zip>60286</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tangerang</city>
        <zip>15224</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tanggerang</city>
        <zip>15811</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11181</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wonju-si</city>
        <state>Gangwon-Do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul,</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sasat</city>
        <zip>13110</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jbeil</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Pilah</city>
        <state>Negeri Sembilan</state>
        <zip>72000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seremban</city>
        <state>Negeri Sembilan</state>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <zip>47301</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Butterworth</city>
        <zip>13000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>57000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>02720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>07300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>09220</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toluca</city>
        <state>Estado de Mexico</state>
        <zip>50010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34078</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Juan</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Makati City</city>
        <zip>1218</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>101953</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>1117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117485</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Riyadh 11426</city>
        <zip>Riyadh 11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rajthevee</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saimai</city>
        <state>Bangkok</state>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06600</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34087</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34296</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Al Ain</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naguanagua/Valencia</city>
        <state>Carabobo</state>
        <zip>2001</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caracas</city>
        <state>Dtto Capital/Municipio Libertador</state>
        <zip>1050</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caracas</city>
        <state>Dtto Capital/Municipio Libertador</state>
        <zip>1053</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <state>Estado Carabobo</state>
        <zip>2001</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Dominican Republic</country>
    <country>Indonesia</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841047&amp;StudyName=Caduet%20vs%20Usual%20Care%20in%20Subjects%20with%20Hypertension%20and%20Additional%20Risk%20Factors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <results_first_submitted>October 6, 2010</results_first_submitted>
  <results_first_submitted_qc>October 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2011</results_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a cluster randomized study: the unit of randomization was the investigator, ie, participants were screened before the investigator was randomized. A total of 136 sites were cluster randomized.</recruitment_details>
      <pre_assignment_details>Prior to group assignment of investigators (who were the unit of randomization), participants were consented and screened for enrollment eligibility; participant selection for enrollment took place before investigator assignment. A total of 1,531 participants were enrolled and attended baseline visit; 1,461 participants received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Caduet</title>
          <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="779"/>
                <participants group_id="P2" count="682">4 participants assigned to Caduet treatment received usual care only during the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible for Efficacy Analysis</title>
              <participants_list>
                <participants group_id="P1" count="760"/>
                <participants group_id="P2" count="657"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="686"/>
                <participants group_id="P2" count="638"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caduet as Assigned</title>
          <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
        </group>
        <group group_id="B2">
          <title>Usual Care as Assigned</title>
          <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="783"/>
            <count group_id="B2" value="678"/>
            <count group_id="B3" value="1461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="450"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="368"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="415"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12</title>
        <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Full Analysis Set (FAS) included all subjects, in either treatment group, who had blood pressure and lipid data from at least 1 follow-up visit. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12</title>
          <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
          <population>Full Analysis Set (FAS) included all subjects, in either treatment group, who had blood pressure and lipid data from at least 1 follow-up visit. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="655"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="8.26"/>
                    <measurement group_id="O2" value="16.3" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was estimated that each study site would on average complete 8 evaluable participants, therefore enrolling 164 sites, 1968 participants would provide at least 90% power to detect a 10% relative reduction in the 10-year predicted risk of total CHD at 12 months (as calculated from the Framingham model) from the control arm based on a two-sided t-test with a 5% significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-4.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.55</ci_lower_limit>
            <ci_upper_limit>-3.89</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Framingham 10-year Risk of Total CHD at Month 4</title>
        <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham 10-year Risk of Total CHD at Month 4</title>
          <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="7.96"/>
                    <measurement group_id="O2" value="16.3" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-4.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.58</ci_lower_limit>
            <ci_upper_limit>-3.93</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12</title>
        <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12</title>
          <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="655"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.89"/>
                    <measurement group_id="O2" value="3.7" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.72</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European SCORE 10-year Risk of Fatal CVD at Month 4</title>
        <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>European SCORE 10-year Risk of Fatal CVD at Month 4</title>
          <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.13"/>
                    <measurement group_id="O2" value="3.7" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Framingham 10-year Risk of Stroke at Month 12</title>
        <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham 10-year Risk of Stroke at Month 12</title>
          <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="655"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.25"/>
                    <measurement group_id="O2" value="4.9" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Framingham 10-year Risk of Stroke at Month 4</title>
        <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham 10-year Risk of Stroke at Month 4</title>
          <description>Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.21"/>
                    <measurement group_id="O2" value="4.9" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>LSMean difference</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
            <estimate_desc>Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Framingham 10-year Risk of Developing Total CHD</title>
        <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
        <time_frame>Baseline, Month 4, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Framingham 10-year Risk of Developing Total CHD</title>
          <description>Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2705" lower_limit="-7.90" upper_limit="-6.64"/>
                    <measurement group_id="O2" value="-2.5155" lower_limit="-3.19" upper_limit="-1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2374" lower_limit="-7.87" upper_limit="-6.61"/>
                    <measurement group_id="O2" value="-2.5167" lower_limit="-3.19" upper_limit="-1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD</title>
        <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
        <time_frame>Baseline, Month 4, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD</title>
          <description>European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>percent risk</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="655"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8438" lower_limit="-2.06" upper_limit="-1.63"/>
                    <measurement group_id="O2" value="-0.9678" lower_limit="-1.20" upper_limit="-0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9693" lower_limit="-2.16" upper_limit="-1.77"/>
                    <measurement group_id="O2" value="-0.9963" lower_limit="-1.21" upper_limit="-0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic and Diastolic Blood Pressure at Month 4</title>
        <time_frame>Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic and Diastolic Blood Pressure at Month 4</title>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.5" spread="14.32"/>
                    <measurement group_id="O2" value="134.5" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" spread="8.74"/>
                    <measurement group_id="O2" value="81.1" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic and Diastolic Blood Pressure at Month 12</title>
        <time_frame>Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic and Diastolic Blood Pressure at Month 12</title>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.6" spread="13.84"/>
                    <measurement group_id="O2" value="134.3" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="8.39"/>
                    <measurement group_id="O2" value="81.1" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) at Month 4</title>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) at Month 4</title>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>mmHG</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3088" lower_limit="-17.02" upper_limit="-13.60"/>
                    <measurement group_id="O2" value="-12.1619" lower_limit="-14.00" upper_limit="-10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.007</p_value>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.42</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4</title>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4</title>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>mmHG</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3024" lower_limit="-9.24" upper_limit="-7.36"/>
                    <measurement group_id="O2" value="-6.6908" lower_limit="-7.70" upper_limit="-5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.011</p_value>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.86</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP at Month 12</title>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS, number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP at Month 12</title>
          <population>FAS, number of participants analyzed refers to number of participants contributing to data.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2409" lower_limit="-19.94" upper_limit="-16.55"/>
                    <measurement group_id="O2" value="-12.4903" lower_limit="-14.32" upper_limit="-10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.00</ci_lower_limit>
            <ci_upper_limit>-3.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DBP at Month 12</title>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP at Month 12</title>
          <population>FAS. Number of participants analyzed refers to number of participants contributing to data.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0128" lower_limit="-10.96" upper_limit="-9.07"/>
                    <measurement group_id="O2" value="-6.8429" lower_limit="-7.86" upper_limit="-5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.42</ci_lower_limit>
            <ci_upper_limit>-1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Lipid Parameters at Month 4</title>
        <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
        <time_frame>Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Lipid Parameters at Month 4</title>
          <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.0" spread="34.14"/>
                    <measurement group_id="O2" value="195.2" spread="37.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" spread="28.47"/>
                    <measurement group_id="O2" value="116.4" spread="32.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="13.93"/>
                    <measurement group_id="O2" value="46.8" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.5" spread="83.26"/>
                    <measurement group_id="O2" value="164.8" spread="95.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.71</ci_lower_limit>
            <ci_upper_limit>-34.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-35.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.64</ci_lower_limit>
            <ci_upper_limit>-30.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effects linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.60</ci_lower_limit>
            <ci_upper_limit>-14.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Lipid Parameters at Month 12</title>
        <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Lipid Parameters at Month 12</title>
          <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.3" spread="38.42"/>
                    <measurement group_id="O2" value="196.6" spread="36.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" spread="32.40"/>
                    <measurement group_id="O2" value="117.3" spread="31.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="13.48"/>
                    <measurement group_id="O2" value="47.1" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" spread="98.61"/>
                    <measurement group_id="O2" value="166.4" spread="98.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.57</ci_lower_limit>
            <ci_upper_limit>-28.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.70</ci_lower_limit>
            <ci_upper_limit>-25.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.379</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.72</ci_lower_limit>
            <ci_upper_limit>-7.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Parameters at Month 4</title>
        <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Parameters at Month 4</title>
          <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="752"/>
                <count group_id="O2" value="630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.7542" lower_limit="-46.35" upper_limit="-39.15"/>
                    <measurement group_id="O2" value="-3.8144" lower_limit="-7.75" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.2765" lower_limit="-41.52" upper_limit="-35.03"/>
                    <measurement group_id="O2" value="-2.9628" lower_limit="-6.50" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2060" lower_limit="-1.07" upper_limit="0.65"/>
                    <measurement group_id="O2" value="-1.1978" lower_limit="-2.13" upper_limit="-0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5645" lower_limit="-27.30" upper_limit="-13.83"/>
                    <measurement group_id="O2" value="3.0828" lower_limit="-4.26" upper_limit="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.71</ci_lower_limit>
            <ci_upper_limit>-34.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-35.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.64</ci_lower_limit>
            <ci_upper_limit>-30.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.60</ci_lower_limit>
            <ci_upper_limit>-14.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Parameters at Month 12</title>
        <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Parameters at Month 12</title>
          <description>Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1024" lower_limit="-40.52" upper_limit="-33.69"/>
                    <measurement group_id="O2" value="-4.0368" lower_limit="-7.71" upper_limit="-0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2420" lower_limit="-36.17" upper_limit="-30.32"/>
                    <measurement group_id="O2" value="-3.4168" lower_limit="-6.58" upper_limit="-0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4339" lower_limit="-1.41" upper_limit="0.54"/>
                    <measurement group_id="O2" value="-1.0105" lower_limit="-2.06" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2270" lower_limit="-23.12" upper_limit="-7.33"/>
                    <measurement group_id="O2" value="3.0398" lower_limit="-5.51" upper_limit="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total cholesterol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.57</ci_lower_limit>
            <ci_upper_limit>-28.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.70</ci_lower_limit>
            <ci_upper_limit>-25.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.379</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.</p_value_desc>
            <method>Mixed-effect linear model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.72</ci_lower_limit>
            <ci_upper_limit>-7.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months</title>
        <description>Goals set at &lt;140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and &lt;140/90 mm Hg or &lt;130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.</description>
        <time_frame>Month 4, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months</title>
          <description>Goals set at &lt;140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and &lt;140/90 mm Hg or &lt;130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JNC Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JNC Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1"/>
                    <measurement group_id="O2" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESC Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESC Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months</title>
        <description>Goal set at &lt;100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at &lt;80 mg/dL according to the European (EU) Society of Cardiology guidelines.</description>
        <time_frame>Month 4, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months</title>
          <description>Goal set at &lt;100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at &lt;80 mg/dL according to the European (EU) Society of Cardiology guidelines.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>US Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>US Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                    <measurement group_id="O2" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EU Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EU Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months</title>
        <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
        <time_frame>Month 4, Month 12</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months</title>
          <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4: anti-hypertensive and/or lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648"/>
                    <measurement group_id="O2" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: anti-hypertensive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647"/>
                    <measurement group_id="O2" value="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: anti-hypertensive and lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: anti-hypertensive and/or lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="655"/>
                    <measurement group_id="O2" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: anti-hypertensive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654"/>
                    <measurement group_id="O2" value="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: anti-hypertensive and lipid lowering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase of Treatment Dosages After 4 Months.</title>
        <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
        <time_frame>Month 4</time_frame>
        <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Caduet</title>
            <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase of Treatment Dosages After 4 Months.</title>
          <description>Treatments indicative of prescribed medications other than study provided Caduet.</description>
          <population>FAS. Number of participants analyzed refers to number of participants contributing data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increased dose of anti-hypertensive medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increased dose of lipid lowering medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increase in either medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increase in both medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Caduet</title>
          <description>Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Normal tension glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Non-Hodgkins lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Upper motor neurone lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="356" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="289" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Refraction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetic enteropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gingival erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urogenital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Nerve root injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>High density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Platelet aggregation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypo HDL cholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Crystal arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Senile osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Sympathetic posterior cervical syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Nerve root lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Tonsillar inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Circumcision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="682"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="779"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

